Warning: The NCBI web site requires JavaScript to function. more...
Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation.
Zilberberg MD, Kothari S, Shorr AF.
Crit Care. 2009;13(3):R94. Epub 2009 Jun 19.
Related citations
High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: a cost-effectiveness analysis.
Chen H, Suda KJ, Turpin RS, Pai MP, Bearden DT, Garey KW.
Curr Med Res Opin. 2007 May;23(5):1057-65.
Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea.
Sohn HS, Lee TJ, Kim J, Kim D.
Clin Ther. 2009 May;31(5):1105-15; discussion 1066-8.
Empirical anti-Candida therapy among selected patients in the intensive care unit: a cost-effectiveness analysis.
Golan Y, Wolf MP, Pauker SG, Wong JB, Hadley S.
Ann Intern Med. 2005 Dec 20;143(12):857-69.
Cost-effectiveness analysis of antifungal prophylaxis in patients undergoing hematopoietic stem cell transplantation.
Schonfeld W, Wang Cheng J, Tong KB, Seifeldin R.
Clin Ther. 2008 May;30(5):964-73.
Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
Reboli AC, Rotstein C, Kett DH, Maschio M, Cartier S, Chambers R, Tarallo M.
Pharmacoeconomics. 2011 Aug;29(8):705-17. doi: 10.2165/11584810-000000000-00000.
Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy. Study Group of Fungal Infection in the ICU.
Nolla-Salas J, Sitges-Serra A, León-Gil C, Martínez-González J, León-Regidor MA, Ibáñez-Lucía P, Torres-Rodríguez JM.
Intensive Care Med. 1997 Jan;23(1):23-30.
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.
Wilke M.
Eur J Med Res. 2011 Apr 28;16(4):180-6. Review.
Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK.
Sidhu MK, van Engen AK, Kleintjens J, Schoeman O, Palazzo M.
Curr Med Res Opin. 2009 Aug;25(8):2049-59.
Empiric anti-Candida therapy for patients with sepsis in the ICU: how little is too little?
Golan Y.
Crit Care. 2009;13(4):180. Epub 2009 Aug 21.
Esophageal candidiasis in patients infected with the human immunodeficiency virus. A decision analysis to assess cost-effectiveness of alternative management strategies.
Rabeneck L, Laine L.
Arch Intern Med. 1994 Dec 12-26;154(23):2705-10.
Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry.
Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, Marr KA, Pfaller MA, Chang CH, Webster KM.
Clin Infect Dis. 2009 Jun 15;48(12):1695-703.
Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006).
Leroy O, Gangneux JP, Montravers P, Mira JP, Gouin F, Sollet JP, Carlet J, Reynes J, Rosenheim M, Regnier B, Lortholary O; AmarCand Study Group.
Crit Care Med. 2009 May;37(5):1612-8.
Management of systemic candidal infections in the intensive care unit.
Kam LW, Lin JD.
Am J Health Syst Pharm. 2002 Jan 1;59(1):33-41. Review.
[Role of anidulafungin in critically ill patients].
Borges Sá M, Garnacho Montero J.
Enferm Infecc Microbiol Clin. 2008 Dec;26 Suppl 14:35-43. Review. Spanish.
Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care Units at a Brazilian University Hospital.
Girão E, Levin AS, Basso M, Gobara S, Gomes LB, Medeiros EA, Costa SF.
Med Mycol. 2008 Sep;46(6):581-8.
Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.
Dupont BF, Lortholary O, Ostrosky-Zeichner L, Stucker F, Yeldandi V.
Crit Care. 2009;13(5):R159. Epub 2009 Oct 5.
Empirical treatment of candidemia in intensive care units: fluconazole or broad-spectrum antifungal agents?
Guinea J, Peláez T, Rodríguez-Créixems M, Torres-Narbona M, Muñoz P, Alcalá L, Bouza E.
Med Mycol. 2009;47(5):515-20.
[Cost effectiveness of posaconazole versus fluconazole/itraconazole in the prophylactic treatment of invasive fungal infections in Mexico].
Rely K, Alexandre PK, Escudero GS.
Value Health. 2011 Jul-Aug;14(5 Suppl 1):S39-42. Spanish.
Cost-effectiveness analysis of anidulafungin versus fluconazole for the treatment of invasive candidiasis.
Neoh CF, Liew D, Slavin M, Marriott D, Chen SC, Morrissey O, Stewart K, Kong DC.
J Antimicrob Chemother. 2011 Aug;66(8):1906-15. Epub 2011 May 30.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on